| 日期 | 股东名称 | 披露原因 | 买入/卖出涉及 的股份数目 |
每股平均价 | 持有权益的 股份数目 |
占已发行 股本(%) |
| 15/08/2025 | China International Capital Corporation Limited | 1701(L) | 2,353,008(L) | 2,353,008(L) | 6.44 | |
| 15/08/2025 | CICC Biomedical Fund L.P. | 1701(L) | 2,353,008(L) | 2,353,008(L) | 6.44 | |
| 15/08/2025 | Henan Zhongjin Huirong Private Equity Fund Management Co., Ltd. | 1701(L) | 2,353,008(L) | 2,353,008(L) | 6.44 | |
| 15/08/2025 | Shanghai Nuotang Biotechnology Co., Ltd. | 1701(L) | +13,074,949(L) | 13,074,949(L) | 35.79 | |
| 15/08/2025 | Shanghai Nuotang Biotechnology Co., Ltd. | 1701(L) | +52,299,799(L) | 52,299,799(L) | 12.44 | |
| 15/08/2025 | Pavilion Capital Holdings Pte. Ltd. | 1701(L) | 25,344,931(L) | 25,344,931(L) | 6.03 | |
| 15/08/2025 | Guangzhou Nuopa Enterprise Management Partnership (Limited Partnership) | 1701(L) | +6,554,929(L) | 6,554,929(L) | 17.94 | |
| 15/08/2025 | KIP KIS SEA-CHINA Fund | 1701(L) | +26,556,444(L) | 26,556,444(L) | 6.32 | |
| 15/08/2025 | KOREA INVESTMENT HOLDINGS Co., Ltd. | 1701(L) | +41,731,556(L) | 41,731,556(L) | 9.93 | |
| 15/08/2025 | WANG QINGHUA | 1701(L) | +30,319,624(L) | 30,319,624(L) | 82.99 | |
| 15/08/2025 | WANG QINGHUA | 1701(L) | +121,278,502(L) | 121,278,502(L) | 28.86 | |
| 15/08/2025 | Hong Kong Invengen Pharmaceutical Technology Co., Limited | 1701(L) | +121,278,502(L) | 121,278,502(L) | 28.56 | |
| 15/08/2025 | KOREA INVESTMENT PARTNERS Co., Ltd. | 1701(L) | +41,731,556(L) | 41,731,556(L) | 9.93 | |
| 15/08/2025 | KOREA INVESTMENT & SECURITIES Co., Ltd | 1701(L) | +26,556,444(L) | 26,556,444(L) | 6.32 | |
| 1 2 | ||||||
| 备注: | (L) - 长仓:包括 (1) 持有股份;(2) 透过持有丶沽出或发行金融合约,有权或有责任购买相关股份。 |
| (S) - 短仓:包括 (1) 借入股份;(2) 透过持有丶沽出或发行金融合约,有权或有责任沽出相关股份。 | |
| (P) - 可供借出的股份 | |
| 即时报价更新时间为 26/08/2026 18:00 | |
| 港股实时基本市场行情由香港交易所提供; 香港交易所指定免费发放实时基本市场行情的网站。 | |